IMNM
Immunome, Inc.NASDAQHealthcare$21.84-2.72%ClosedMarket Cap: $1.92B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.01
P/S
276.46
EV/EBITDA
-6.08
DCF Value
$7.38
FCF Yield
-10.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-630.3%
Operating Margin
-3084.8%
Net Margin
-3060.0%
ROE
-57.6%
ROA
-31.1%
ROIC
-33.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-62.9M | $-69.9M | $-0.76 | — |
| FY 2025 | $6.9M | 57.4% | $-214.1M | $-212.4M | $-2.43 | — |
| Q3 2025 | $0.00 | -Infinity% | $-60.1M | $-57.5M | $-0.65 | — |
| Q2 2025 | $4.0M | 82.1% | $-46.5M | $-43.4M | $-0.50 | — |
| Q1 2025 | $2.9M | 100.0% | $-44.6M | $-41.6M | $-0.52 | — |
| Q4 2024 | $2.7M | 100.0% | $-83.0M | $-80.2M | $-1.28 | — |
| FY 2024 | $9.0M | 100.0% | $-305.8M | $-293.0M | $-5.00 | — |
| Q3 2024 | $2.9M | 100.0% | $-50.5M | $-47.1M | $-0.78 | — |
| Q2 2024 | $2.4M | 100.0% | $-40.0M | $-36.1M | $-0.60 | — |
| Q1 2024 | $1.0M | 100.0% | $-132.3M | $-129.5M | $-12.56 | — |
| Q4 2023 | $3.8M | 100.0% | $-94.7M | $-92.6M | $-4.22 | — |
| FY 2023 | $14.0M | 100.0% | $-109.5M | $-106.8M | $-5.38 | — |